Akari Therapeutics (AKTX) Shares Outstanding (Weighted Average) (2011 - 2026)

Akari Therapeutics has disclosed Shares Outstanding (Weighted Average) across 16 years of filings, most recently posting $118.8 billion for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $118.8 billion, up 117.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.8 billion (up 117.55% YoY), and the FY2025 annual result was $67.3 billion, up 181.85% from the prior year.
• Shares Outstanding (Weighted Average) came in at $118.8 billion for Q1 2026 at Akari Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $118.8 billion in Q1 2026 to a low of $1.7 million in Q4 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $14.8 billion (2024), against an average of $29.4 billion.
• Peak annual rise in Shares Outstanding (Weighted Average) reached 305.77% in 2025, while the deepest fall reached 99.99% in 2025.
• Akari Therapeutics' Shares Outstanding (Weighted Average) stood at $6.2 billion in 2022, then surged by 56.79% to $9.8 billion in 2023, then surged by 144.03% to $23.9 billion in 2024, then slumped by 99.99% to $1.7 million in 2025, then jumped by 7082099.56% to $118.8 billion in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $118.8 billion (Q1 2026), $1.7 million (Q4 2025), and $61.0 billion (Q3 2025), per Business Quant data.